Company / Depreciation & Amortization
Denali Therapeutics Inc. Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$11.2M
FY2025
5-year range
$7.8M / $16.7M
FY2021-FY2025
Trend
+43.5%
vs FY2024
Sector context
#62 of 163
Health Care
What the data says
At $11M, Denali Therapeutics Inc.'s depreciation & amortization ranks #102 of 163 in the Health Care sector. Depreciation & Amortization has fluctuated over the past 10 years, ranging from $1M in FY2018 to $17M in FY2023.
Based on SEC 10-K filings.
$11M in FY2025 with a 5-year CAGR of +8.6%.
Improved from $17M to $11M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +9.4%
- 5-Year CAGR
- +8.6%
- 10-Year CAGR
- -
Sector benchmark
#102 of 163 in Health CareTop 62% of 163This company $11.2M Sector average $219.4M
▼
-94.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +8.6%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 43.5% year-over-year.
- Ranks #62 out of 163 companies in the Health Care sector.
- Peak depreciation & amortization was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.2M | +43.5% |
| FY2024 | $7.8M | -53.4% |
| FY2023 | $16.7M | +96.1% |
| FY2022 | $8.5M | +6.8% |
| FY2021 | $8.0M | +7.8% |
| FY2020 | $7.4M | +140.6% |
| FY2019 | $3.1M | +109.8% |
| FY2018 | $1.5M | -52.3% |
| FY2017 | $3.1M | +109.8% |
| FY2016 | $1.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026